Pfizer Lung Cancer Drug to Get Priority Review
Arlene Weintraub5/17/11
New York-based Pfizer (NYSE: PFE) announced that it has simultaneously applied for approval of its lung cancer drug, crizotinib, in the U.S. and Japan, and that the FDA granted it priority review. Crizotinib is the first in a new class of drugs called anaplastic lymphoma kinase (ALK) inhibitors, and it is being developed for a subset of patients with ALK-positive advanced non-small cell lung cancer (NSCLC). The goal of priority review is for the FDA to render its verdict within six months, rather than the usual 10. Four analysts surveyed by Bloomberg estimated that crizotinib could bring in $755 million in annual sales by 2015.
Pingback: Pfizer cancer drug takes big step toward fateful FDA decision – FierceBiotech
Pingback: FDA Grants Accelerated Review For Pfizer Cancer Drug – Automated Trader
Pingback: FDA Grants Accelerated Review For Pfizer Cancer Drug – Wall Street Journal
Pingback: Scientists identify possible human lung stem cell (AP) | Search Engine Course
Pingback: Pfizer accelerates Crizotinib regulatory procedures – Pharmaceutical Business Review
Pingback: Pfizer Lung Cancer Drug to Get Priority Review – Xconomy
Pingback: Scientists identify possible human lung stem cell (AP) | Perth University Arts